


Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:


1. (Currently amended) A compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

R¹ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₃ alkyl, substituted C₃-C₇ cycloalkyl-C₁-C₃ alkyl, phenyl substituted with one to three halo substituents, substituted phenyl, heterocycle, or substituted heterocycle;

R² is hydrogen, or C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II



II;

R³ is hydrogen or methyl C₁-C₃ alkyl;

R⁴ is hydrogen, halo, or C₁-C₃ alkyl; and


R⁵ is hydrogen or C₁-C₃ alkyl;

R⁶ is hydrogen or C₁-C₆ alkyl; and

~~n is an integer from 1 to 6 inclusively.~~

2. - 12. (Canceled)


13. (Withdrawn, currently amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

R¹ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl C₁-C₃ alkyl, substituted C₃-C₇ cycloalkyl C₁-C₃ alkyl, phenyl, substituted with one to three halo substituents, phenyl, heterocycle, or substituted heterocycle;

R² is hydrogen, or C₁-C₃ alkyl, C₃-C₆ cycloalkyl C₁-C₃ alkyl, or a group of formula II



R³ is hydrogen or methyl C₁-C₃ alkyl;

R⁴ is hydrogen, halo, or C₁-C₃ alkyl; and

R⁵ is hydrogen or C₁-C₃ alkyl;

R⁶ is hydrogen or C₁-C₆ alkyl; and


~~n is an integer from 1 to 16 inclusively.~~

14. (Withdrawn) The method according to Claim 13 wherein the mammal is a human.

15-26. (Canceled)


27. (Withdrawn) A process for preparing a 2-halo-6-(piperidin-4-carbonyl)pyridine

compound of formula III



where X is bromo or chloro;

R⁸ is an amino protecting group, C₁-C₃ alkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, or a group of formula II




R⁶ is hydrogen or C₁-C₆ alkyl; and

n is an integer from 1 to 6 inclusively;

comprising

- 1) reacting a 2,6-dihalopyridine selected from 2,6-dibromopyridine and 2,6-dichloropyridine, with n-butyl lithium to form 2-halo-6-lithium-pyridine, and then
- 2) reacting the 2-halo-6-lithium-pyridine with a substituted aminocarbonylpiperidine compound of formula IV



wherein R⁹ and R¹⁰ are each methyl, or R⁹ and R¹⁰, together with the nitrogen to which they are attached, combine to form azetidinyl, pyrrolidinyl, or piperidinyl.

28. (Withdrawn) The process of Claim 27 wherein X is bromo and the 2,6-dihalopyridine is 2,6-dibromopyridine.


29. (Withdrawn) The process of Claim 27 wherein R⁹ and R¹⁰ are each methyl.

30. (Withdrawn) The process of Claim 27 wherein R⁹ and R¹⁰, together with the nitrogen to which they are attached, combine to form pyrrolidinyl.

31. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is methyl-*t*-butylether.


32. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is toluene.

33. (Withdrawn) A method for preparing a 2-bromo-6-(piperidin-4-carbonyl)pyridine compound of formula III



wherein R⁷ is C₁-C₃ n-alkyl, or an amino protecting group;

comprising reacting 2,6-dibromopyridine with n-butyl lithium to form 2-bromo-6-lithium-pyridine, and then reacting the 2-bromo-6-lithium-pyridine with a 4-(N,N'-dimethylamino)carbonyl piperidine compound of formula IV



IV;

in a methyl-*tert*-butyl ether solvent.

- 34. (Withdrawn) The process of Claim 28 wherein R⁹ and R¹⁰ are each methyl.
- 35. (Withdrawn) The process of Claim 28 wherein R⁹ and R¹⁰, together with the nitrogen to which they are attached, combine to form pyrrolidinyl.
- 36. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is methyl-*t*-butylether.
- 37. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is methyl-*t*-butylether.
- 38. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is methyl-*t*-butylether.
- 39. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is methyl-*t*-butylether
- 40. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is methyl-*t*-butylether.
- 41. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is toluene.
- 42. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is toluene.
- 43. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is toluene.
- 44. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is toluene.
- 45. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is toluene.

46. - 54. (Canceled).

55. (Currently amended) A pharmaceutical formulation comprising a compound of Claim 1 ~~any one of Claims 1-4, 6, 7, 4[[6]]9-54~~ and a pharmaceutical carrier, diluent, or excipient.

56. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide or a pharmaceutically acceptable acid addition salt thereof.

57. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hemisuccinate salt.

58. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hydrochloride salt.

59. (New) A pharmaceutical formulation comprising a compound of Claim 56 and a pharmaceutical carrier, diluent, or excipient.

60. (New) A pharmaceutical formulation comprising a compound of Claim 57 and a pharmaceutical carrier, diluent, or excipient.

61. (New) A pharmaceutical formulation comprising a compound of Claim 58 and a pharmaceutical carrier, diluent, or excipient.